Skip Ribbon Commands
Skip to main content
Menu
Clin Assoc Prof Claramae Chia Shulyn

Clin Assoc Prof Claramae Chia Shulyn

 MBBS (S'pore), MRCS (Edin), MMed (Surgery), FRCS (Edin)

Senior Consultant

Head and Senior Consultant

National Cancer Centre Singapore

Specialty: Surgery & Surgical Oncology, Sarcoma, Peritoneal and Rare Tumours (SPRinT)

Sub-specialties: Colorectal, Peritoneal-based Malignancies, Upper Gastrointestinal, Sarcoma, Skin & Melanoma, Gastrointestinal, Gastrointestinal Oncology, General Surgery, Melanoma, Pelvic & Peritoneal, Sarcoma/Skin

Conditions Treated by this Doctor:
Anal Cancers, Colorectal Cancer, Gastrointestinal Stromal Tumour (GIST), Melanoma, Ovarian Cancer, Peritoneal based Malignancies, Sarcoma, Skin Cancer, Stomach Cancer.

Clinical Appointments

  • Head & Senior Consultant Sarcoma, Peritoneal and Rare Tumours (SPRinT) Singapore General HospitalSingapore General Hospital
  • Senior Consultant Division of Surgery & Surgical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Visiting Consultant KK Women's and Children's HospitalKK Women's and Children's Hospital

Academic Appointments

  • Adjunct Assistant Prof, Yong Loo Lin School of Medicine, National University of Singapore
  • Adjunct Teaching faculty, Lee Kong Chian School of Medicine
  • Clinical Research Fellow, Wee Kim Wee Laboratory of Surgical Oncology, NCCS
  • Clinical Physician Faculty Member, Transitional Year, SingHealth Residency Programme
  • Clinical Associate Professor

Profile

Dr Claramae Chia is the Head and Senior Consultant in the Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore. She graduated from the National University of Singapore in 2005. She obtained her membership diploma for surgery in 2008 from the Royal College of Surgeons of Edinburgh. In May 2013, she completed her advanced surgical training and joined as a Fellow of the Royal College of Surgeons of Edinburgh. She continued on to her subspecialty training in surgical oncology with a focus on peritoneal surface malignancies. In 2013, she was awarded the SingHealth Health Manpower Development Plan - Peritoneal Surface Malignancy Surgical Oncology Programme. She trained at the Centre Hospitalier Lyon Sud in Lyon, France with Professor Olivier Glehen. Under her leadership, the SPRinT department was formed in 2019 in recognition of the advanced oncological work that the team had been performing. Dr Chia and the SPRinT department continue to push clinical boundaries by introducing new services and initiatives. Examples of this include the introduction of Pressurised Intraperitoneal Aerolised Chemotherapy(PIPAC) and a focus of palliative surgical care.

On the research front, she has been actively involved in clinical as well as basic science research since her basic surgical training. She has had publications in several peer reviewed journals. In 2008, she joined the Wee Kim Wee Laboratory of Surgical Oncology at the National Cancer Centre as a clinical research fellow and won the Singapore Millennium Foundation Grant for Associate Investigator for her translational work in nasopharyngeal carcinoma. In Sprint, Dr Chia continues to remain actively involved in research with the focus on peritoneal surface malignancies, retroperitoneal sarcoma and advanced / pelvic malignancies. She has published more than 70 manuscripts over the course of her research. The department also runs several clinical trials in peritoneal surface malignancies. Dr Chia is also a strong advocate of teaching the next generation of surgeons and doctors. She contributes to the General Surgical Residency Program and is actively involved in teaching medical students from all 3 local medical schools. She is also the first and only mentor in an Asian institute under the European School of Peritoneal Surface Oncology (ESPSO).

Education

  • Royal College of Surgeons (Edinburgh), FRCS, 2016
  • National University of Singapore (Yong Loo Lin School of Medicine), Master of Medicine, 2016
  • University of Cambridge (Oncology), PhD, 2013
  • Royal College of Surgeons (Edinburgh), MRCS, 2008
  • National University of Singapore (Yong Loo Lin School of Medicine), MBBS, 2004

Professional Appointments and Committee Memberships

  • Member for Undergraduate Curriculum Committee (UCC), 2021
  • Chairman for National Cancer Centre Singapore Practice of Anesthesia Review Committee, 2021
  • Deputy Chairperson for NCCS Disease Outbreak Response System (DORS), 2021
  • DSSO Specialist Outpatient Clinic Workgroup, Co-lead, 2021
  • Mentor for ESPSO Training Programme, European School of Peritoneal Surface Oncology (ESPSO), 2021
  • Clinical Competency Committee (CCC) for Residency, 2020
  • Group 1 "Our National Role" Standing Committee for the 2019 Singhealth Duke-NUS Strategy Retreat, 2019
  • Member for Singhealth Procedural Safety Workgroup (SPSW), 2019
  • Deputy Chairperson for NCCS Disease Outbreak Response System (DORS), 2018
  • Committee member for Cancer Service Line Development Workgroup for Gastrointestinal, 2017
  • Committee member for Cancer Service Line Development Workgroup for Sarcoma/ Melanoma, 2017
  • Organising Committee for the Annual Peritoneal Surface Malignancy Conference, 2017
  • Member, Asia Peritoneal Surface Malignancy Group, 2017
  • Member, Society of Surgical Oncology International, 2015
  • Member, European Society of Surgical Oncology, 2015
  • Member, International Association of Surgeons, Gastroenterologists and Oncologists(IASGO), 2014
  • Surgeons-In-Training Committee Chairperson, Chapter of Surgeons Singapore, 2010
  • Medical Officer Committee, Singapore Medical Association, 2008
  • Member, Singapore Medical Association, 2005
  • Chairman of Organising Committee for Charity Movie Screening & Treasurer of Organising Committee for Tri-faculty Bash, Medical Society, 2001
  • Member, Gifted Education Program Alumni Association, 2000

Awards

  • Winner of Young Surgeon's Award 2013
  • 2nd AMM-AMS-HKAM Tripartite Congress & 47th Singapore Malaysia Congress of Medicine, 2013
  • SingHealth Health Manpower Development Plan - Peritoneal Surface Malignancy Surgical Oncology Programme, 2013
  • Singhealth Best Registrar Award, 2012
  • Singapore Millennium Foundation Scholarship (Associate Investigator), 2009
  • Singhealth House Officer Award at the 2006 Department of General Surgery, Singapore General Hospital, 2006
  • NUS Medical Society Colours Award, 2002

Research Interests

  • Peritoneal surface malignancies
  • Retroperitoneal sarcoma
  • Advanced / pelvic malignancies

Publications

  • Lim HJ*, Ong C-AJ*, Skanthakumar T, Mak LYH, Wasudevan SD, Tan JWS, Chia CS, Tan GHC, Teo MCC. Retrospective quality of life study in patients with retroperitoneal sarcoma in an Asian population. Health Qual Life Out. 2020. JIF: 2.318.
  • Ragavan S*, Lim HJ*, Tan JWS, Hendrikson J, Chan JY, Farid M, Chia CS, Tan GHC, Soo KC, Teo MCC, Ong C-AJ (* Equal contribution). Axillary Lymph Node Dissection in Angiosarcomas of the Breast: An Asian Institutional Perspective. Sarcoma 2020: 4890803.
  • Chin KM, Tan GHC, Chia CS, Ong JCA, Teo MCC. Novel prognostic score for outcomes after cytoreductive surgery and HIPEC for colorectal cancer with metachronous peritoneal carcinomatosis. ANZ Journal of Surgery. 11 March 2020. JIF: 1.605.
  • Ong CAJ*, Tan QX*, Lim HJ*, Shannon NB, Lim WK, Hendrikson J, Ng WH, Tan JWS, Koh KKN, Wasudevan SD, Ng CCY, Rajasegaran V, Lim TKH, Ong CK, Kon OL, Teh BT, Tan GC, Chia CS, Soo KC, Teo MCC (* Equal contribution). An optimised protocol harnessing laser capture microdissection on matched primary and metastatic colorectal tumours. Sci Rep 2020;10:682. JIF: 4.011.
  • Wong J, Tan G, Chia CS, Ong J, Ng WY, Teo MCC. The Importance of Synchronicity in the Management of Colorectal Peritoneal Metastases with Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy. World J Surg Oncol 2020;18:10. JIF: 1.966.
  • Tan JWS*, Tan GHC*, Ng WY, Ong CAJ, Chia CS, Soo KC, Teo MCC (* Equal contribution). High grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Clin Oncol. 2020;25(5):984-994. JIF: 2.503.
  • Yong ZZ, Tan GHC, Shannon N, Chia C, Teo MCC. P.R.O.P.S.? A novel pre-operative predictive score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 2019World J Surg Onco 2019;17: 138. JIF: 1.966.
  • Shannon NB*, Tan JWS*, Tan HL*, Wang W, Chen Y, Lim HJ, Tan QX, Hendrikson J, Ng WH, Loo LY, Skanthakumar T, Wasudevan SD, Kon OL, Lim TKH, Tan GHC, Chia CS, Soo KC, Ong C-AJ**, Teo MCC** (* Equal contribution, ** Co-corresponding author). A set of molecular markers predicts chemosensitivity to Mitomycin-C following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis. Sci Rep 2019;9:10572. JIF: 4.011.
  • Tan HL, Chia CS, Tan GHC, Choo SP, Tai DW, Chua CWL, Ng MCH, Soo KC, Teo MCC. Metastatic gastric cancer: does the site of metastasis make a difference? Asia-Pac J Clin Onco 2019;15(1): 0-17. JIF: 1.539.
  • Lee ZJ, Chia CS, Tan GHC, Soo KC, Teo MCC. Cost effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2018;25(8): 2340-2346. JIF: 3.681.

Research Trials

  • Radical resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of high risk recurrent retroperitoneal sarcoma (Ongoing, Study role: PI)
  • Pilot Study: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancers at high risk of developing peritoneal metastases (Ongoing, Study role: PI)
  • Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin and in combination with Nivolumab in patients with peritoneal carcinomatosis (PIANO) (Ongoing, Study role: Co-I)